CYTH News and Press, Cyclo Therapeutics Inc. From 01/11/23

Continued progress in ongoing pivotal Phase 3 global study (TransportNPC™) evaluating Trappsol ® Cyclo™ for Niemann-Pick Disease Type C1 (NPC1) with 35% of expected enrollment completed, on track to complete enrollment by year end 2023 Patient enrollment and dos...

Live video webcast on Thursday, January 19 th at 11:00 AM ET Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and in...

– Biologic similarities demonstrated between Niemann-Pick Disease Type C and Alzheimer’s disease, including cholesterol accumulation in regions of the brain, elevated levels of Tau in CSF, and amyloid plaques in the brain, bolsters rationale for studying Trappsol ® Cyclo&#x...

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced the closing of its previously ...

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced its ...

Cyclo Therapeutics ( NASDAQ: CYTH ) on Friday said it had entered into a securities purchase agreement for 2.6M shares of its common stock at a purchase price of $1.61/share. The agreement is a registered direct offering priced at-the-market under Nasdaq rules, CYTH said in a statem...

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that it has entered into a def...

Cyclo Therapeutics press release ( NASDAQ: CYTH ): Q3 net loss of $4.2M. The company expects research and development to further increase in 2022 as we continue to seek regulatory approval for the use of Trappsol ® Cyclo™ in the treatment of NPC and Alzheim...

– Quarter marked by launch of Phase 2b study of Trappsol ® Cyclo™ for the treatment of early Alzheimer’s Disease (AD) with patient enrollment and site activation now underway – Building momentum with ongoing advancement of global pivotal st...

– Data published in official journal of the Society for Inherited Metabolic Disorders, Molecular Genetics and Metabolism – Published trial data show that Trappsol ® Cyclo™ overcomes the NPC1 defect by removing trapped cholesterol from cells both s...